SecBot SecBot
DEFA14A ·Filed Apr 24, 2026

ATRA

Atara Biotherapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed6mo ago SEC0001193125-26-177280
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the vote results for the equity incentive plan increase, as approval could lead to share dilution. The other proposals are standard governance items unlikely to impact operations.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.99
T+0 close · Apr 24, 2026 · via day close
Latest settled
+62.83%
T+60 · $8.13
Vs SPY
+58.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $4.99entry
  2. T+1 · 7mo ago −5.21%α −4.73% · $4.73
  3. T+5 · 7mo ago −2.20%α −2.60% · $4.88
  4. T+20 · 6mo ago +92.59%α +87.63% · $9.61
  5. T+60 · 4mo ago +62.83%α +58.05% · $8.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atara Biotherapeutics is holding its 2026 annual meeting to vote on four key proposals: electing two directors, approving executive compensation, increasing shares in its equity incentive plan by 400,000, and ratifying Deloitte & Touche as its auditor. The filing is a routine proxy statement from management.

Key Financial Metrics

Vote
director election
Meeting
2026-06-09

Key Facts

  • Annual meeting to vote on director elections, executive compensation, equity plan increase, and auditor ratification
  • Management is soliciting votes for all proposals
  • No activist involvement or contested board seats
  • Routine annual corporate governance matters

Financial Impact

400,000 additional shares authorized in equity incentive plan

dilutionexecutive compensationgovernance

Risk Factors

  • Potential share dilution from the equity plan increase
  • Shareholder opposition to executive compensation

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-177280
Document: 0001193125-26-177280-index-headers.html0001193125-26-177280
Document: 0001193125-26-177280-index.html0001193125-26-177280
Document: 0001193125-26-177280.txt0001193125-26-177280

Track record

11 reports on ATRA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
  3. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
  4. Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
  5. May 7, 202627w ago 8-K Neutral 4/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  6. May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Viewing Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
  8. Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
  9. Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
  10. Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026